



Michael T. Flavin

Michael T. Flavin is CEO of Shamrock Structures, a protein crystallography research services company founded in 2003 by Flavin Ventures to provide pharmaceutical researchers with access to technologies and expertise for three-dimensional protein structure determinations. Scientists need such drug-target information to conduct computer-aided studies to design, synthesize, test and market better new drugs to treat disease. Shamrock Structures' technology-driven structural biology research systems help pharmaceutical companies accelerate the drug discovery process.

Dr. Flavin is also Chairman & CEO of Advanced Life Sciences (ADLS.OB), a biopharmaceutical company focused on the development of new drugs to fight infection, inflammation and cancer. Founded in 1999, Advanced Life Sciences completed a \$35M IPO in August, 2005 and several follow-on financings to advance drugs through clinical trials, including RestanzaTM (cethromycin), a novel once-a-day oral antibiotic in NDA-stage development for the treatment of respiratory tract infections including community acquired bacterial pneumonia.

In 1987, Dr. Flavin founded MediChem Life Sciences (NASDAQ: MCLS). He established MediChem as a premier drug discovery and development company for the pharmaceutical industry. Over 14 years, MediChem grew from a two-person operation to more than 240 employees, serving over 90 clients in drug discovery, including most of the world's largest pharmaceutical companies and many leading biotechnology firms. In 2000, he oversaw the acquisition and integration of ThermoGen, a protein expression company, and Emerald Biostructures, a structural biology company, as MediChem subsidiaries. In October, 2000, MediChem completed a \$54M IPO. MediChem was acquired in 2002 by deCODE genetics (NASDAQ:DCGN) to build a complete "gene map to drug" business model.

Dr. Flavin has 45 publications in scientific journals and 20 U.S. patents in the fields of organic chemistry, medicinal chemistry and biochemistry. He has been awarded several grants from the National Institutes of Health to further his research in HIV, hepatitis B and cancer drug discovery. Dr. Flavin is also the recipient of several awards, including the Sr. Margaret Wright Graduate Award from the University of Illinois, the Chicago Area Entrepreneurship Hall of Fame and the Year 2000 Illinois High Tech Award.

Dr. Flavin received his B.S. degree in chemistry from Notre Dame and his Ph.D. degree in medicinal chemistry from University of Illinois at Chicago. After completing his postdoctoral fellowship at Harvard, he was a Senior Research Scientist at Baxter prior to founding MediChem.